C4 Therapeutics says cemsidomide posts 53% response rate in Phase 1 relapsed/refractory multiple myeloma trial at 100 µg dose

C4 Therapeutics

CCCC

0.00

C4 Therapeutics will present further Phase 1 data on cemsidomide in relapsed or refractory multiple myeloma at EHA 2026 on June 12.
The analysis from a fully enrolled study showed meaningful tumor responses in heavily pretreated patients, including deepening responses over time.
Safety looked manageable, with limited treatment changes tied to tolerability, supporting continued development across later-line settings.
The company positioned cemsidomide as a potential backbone therapy, including use in combinations with existing multiple myeloma drugs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606110700PRIMZONEFULLFEED9735251) on June 11, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.